Group 1 - The core point of the announcement is that shareholder Paradise Silicon Valley has completed its plan to reduce its holdings by selling a total of 1.6227 million shares, which represents 2.0039% of the total share capital [1] - As of September 10, 2025, the shareholder has sold 809,700 shares through centralized bidding and 813,000 shares through block trading, achieving the total reduction of 1.6227 million shares [1] - Following the completion of the reduction plan, Paradise Silicon Valley currently holds 0 shares in the company [1]

Core Points - Anjias (688581.SH) announced the completion of a share reduction plan by its shareholder, Paradise Silicon Valley, as of September 10, 2025 [1] Summary by Category Shareholder Actions - Paradise Silicon Valley reduced its holdings by a total of 1,622,700 shares, which represents 2.0039% of the total share capital [1] - The reduction included 809,700 shares sold through centralized bidding, accounting for 0.9999% of the total share capital [1] - Additionally, 813,000 shares were sold via block trading, making up 1.0040% of the total share capital [1]

证券代码：688581 证券简称：安杰思 公告编号：2025-059 杭州安杰思医学科技股份有限公司 关于股东减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 股东持有的基本情况 本次减持计划实施前，公司杭州天堂硅谷创业投资管理有限公司－宁波天堂 硅谷正汇股权投资合伙企业（有限合伙）（以下简称"天堂硅谷"）持有公司股份 1,622,700 股，占公司总股本的 2.0039%，其中持有的股份来源为公司首发前股份 数 1,159,071 股，通过公司 2023 年年度派送红股获得的股份数 463,629 股，上述 股东持有的公司首发前股份已于 2024 年 5 月 20 日解除限售并上市流通。 减持计划的实施结果情况 2025 年 7 月 3 日，公司于上海证券交易所网站（www.sse.com.cn）披露了《杭 州安杰思医学科技股份有限公司股东减持股份计划公告》（公告编号：2025-045）。 因企业自身的经营安排，股东天堂硅谷拟合计减持公司股份不超过 1,622,700 股 （即 ...

Group 1 - The core point of the news is that the main funds in the Shanghai and Shenzhen markets saw a net inflow of 34.518 billion yuan, with the Sci-Tech Innovation Board experiencing a net inflow of 2.309 billion yuan [1] - A total of 230 stocks on the Sci-Tech Innovation Board saw net inflows, while 358 stocks experienced net outflows [1] - Among the stocks with significant net inflows, Haiguang Information led with a net inflow of 2.467 billion yuan, followed by Shijia Photon and Dingtong Technology with net inflows of 369 million yuan and 234 million yuan respectively [1] Group 2 - There are 37 stocks that have seen continuous net inflows for more than three trading days, with Hanwujing leading at 17 consecutive days of inflow [2] - Conversely, 150 stocks have experienced continuous net outflows, with Xianfeng Precision leading at 14 consecutive days of outflow [2] - The top three stocks by net inflow include Haiguang Information, Shijia Photon, and Dingtong Technology, with inflows of 246.719 million yuan, 36.891 million yuan, and 23.406 million yuan respectively [2] Group 3 - The overall market performance shows that 524 stocks on the Sci-Tech Innovation Board rose, with six stocks hitting the daily limit up, including Juguang Technology and Tengjing Technology [1] - The stock with the largest net outflow was BeiGene, which saw a net outflow of 229 million yuan and a decline of 3.73% [1] - Other notable stocks with significant net outflows include Jiayuan Technology and Tianyue Advanced, with outflows of 215 million yuan and 147 million yuan respectively [1]

Core Points - Anjie Technology announced the resignation of employee representative director Han Chunqi due to internal work adjustments [2] - Han Chunqi will continue to serve as a senior management personnel after resigning from the board and its committees [2] - The company held its third employee representative assembly on September 10, 2025, where Bai Ming was elected as the new employee representative director [2] - Bai Ming's term will align with the term of the third board of directors elected at the 2024 annual shareholders' meeting [2]

Core Viewpoint - Hangzhou Anjisi Medical Technology Co., Ltd. has established a detailed share repurchase system to promote standardized operations, complying with relevant laws and regulations [1] Group 1: Repurchase Conditions and Principles - The company’s share repurchase is primarily applicable for reducing registered capital, employee stock ownership or equity incentives, convertible bond conversions, and maintaining company value and shareholder rights [2] - Specific conditions for repurchase to maintain company value include: stock closing price below the latest net asset per share, cumulative decline of 20% over 20 consecutive trading days, and below 50% of the highest closing price in the past year [2] - The repurchase must comply with relevant regulations, not harm the rights of shareholders and creditors, and must follow decision-making procedures and information disclosure obligations [2] Group 2: Implementation Procedures and Disclosure - Proposals for share repurchase can be made by eligible proposers to the board, which must promptly review and announce related content [3] - The repurchase plan must include detailed information such as purpose, method, price range, and funding sources, and must be disclosed within a specified timeframe [3] - Changes or termination of the repurchase plan require proper justification and must be submitted for review [3] Group 3: Handling of Repurchased Shares - Repurchased shares must be handled according to disclosed purposes, either transferred or canceled, with specific conditions for sale after a designated period [4] - Sale of repurchased shares must adhere to relevant requirements, including price declaration, sale timing, and quantity restrictions, with timely disclosure of sale progress and results [4] Group 4: Daily Supervision - The company and related parties must manage insider information and report relevant insider information when disclosing the repurchase plan [4] - The newly established share repurchase system provides clear operational guidelines for potential future repurchase actions, helping to protect the legal rights of the company and its shareholders, and promoting healthy and stable development [4]

Group 1 - The company Anjiasi (SH 688581) announced the resignation of Mr. Han Chunqi from his position as employee representative director due to internal adjustments, while he will continue to serve as a senior management personnel [1] - To maintain the integrity of the corporate governance structure, the company held an employee representative meeting on September 10, 2025, where Mr. Shi Baoming was elected as the employee representative director for the third board of directors [1] - For the fiscal year 2024, Anjiasi's revenue composition was 99.41% from medical devices and 0.59% from other businesses [1] Group 2 - As of the latest report, Anjiasi's market capitalization is 6 billion yuan [2]

2025年9月11日 杭州安杰思医学科技股份有限公司（以下简称"公司"）监事会依据《中华人 民共和国公司法》（以下简称"《公司法》"）《中华人民共和国证券法》（以下 简称"《证券法》"）《上市公司股权激励管理办法》（以下简称"《管理办法》"） 《上海证券交易所科创板股票上市规则》（以下简称"《上市规则》"）《杭州安 杰思医学科技股份有限公司2023年限制性股票激励计划（草案）》等相关法律、 法规、规章及规范性文件和《杭州安杰思医学科技股份有限公司章程》（以下简 称"《公司章程》"）的有关规定，对公司2023年限制性股票激励计划（以下简称 "本次激励计划"）首次授予部分第二个归属期及预留授予部分第一个归属期归属 名单进行审核，发表核查意见如下： 除2名激励对象因离职丧失激励对象资格，10名激励对象绩效考核不达标， 不符合归属条件外，本次拟归属的64名首次授予激励对象和18名预留授予激励对 象符合《公司法》《证券法》等法律、法规和规范性文件以及《公司章程》规定 的任职资格，符合《管理办法》《上市规则》等法律、法规和规范性文件规定的 激励对象条件，符合本次激励计划规定的激励对象范围，其作为公司本次限制性 股票激励计 ...

证券代码：688581 证券简称：安杰思 公告编号：2025-050 杭州安杰思医学科技股份有限公司 关于调整 2023 年限制性股票激励计划 相关事项的公告 1、2023 年 8 月 14 日，公司召开第二届董事会第六次会议，审议通过了《关于 公司<2023 年限制性股票激励计划（草案）>及其摘要的议案》《关于公司<2023 年限制性股票激励计划实施考核管理办法>的议案》《关于提请股东大会授权董事 会办理 2023 年限制性股票激励计划相关事项的议案》。公司独立董事对本次激励 计划相关议案发表了独立意见。 同日，公司召开第二届监事会第四次会议，审议通过了《关于公司<2023 年限 制性股票激励计划（草案）>及其摘要的议案》《关于公司<2023 年限制性股票激 励计划实施考核管理办法>的议案》《关于核实公司 2023 年限制性股票激励计划激 励对象名单的议案》等议案。公司监事会对本激励计划的相关事项进行核实并出具 了相关核查意见，律师出具了相应的法律意见书。 公司于 2023 年 8 月 16 日在上海证券交易所网站（www.sse.com.cn）披露了相 关公告。 2、2023 年 8 月 16 日，公司于 ...

董事会议事规则 第一条 宗旨 杭州安杰思医学科技股份有限公司 董事会议事规则 杭州安杰思医学科技股份有限公司 为进一步规范杭州安杰思医学科技股份有限公司（以下简称"公司"）董事 会的议事方式和决策程序，促使董事和董事会有效地履行其职责，提高董事会规 范运作和科学决策水平，根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《杭州安杰思医学科技股份有限公司章程》（以下简称"《公司章程》"）等有关 规定，制订本规则。 第二条 董事会办公室 1 董事会下设董事会办公室，处理董事会日常事务。 董事会秘书兼任董事会办公室负责人，保管董事会和董事会办公室印章。董 事会秘书可以指定证券事务代表等有关人员协助其处理日常事务。 第三条 董事会的职权 董事会行使下列职权： （六） 拟订公司重大收购、收购本公司股票或者合并、分立、解散及变更 公司形式的方案； （七） 在股东会授权范围内，决定公司对外投资、收购出售资产、资产抵 押、对外担保、委托理财、关联交易等事项； （八） 决定公司内部管理机构的设置； （九） 决定聘任或者解聘公司总经理、董事会秘书及其他高级管理人员， 并决定其报酬事项和奖惩事项；根据总经理的提名，聘任或者 ...